How does SaiyanMed select independent testing labs?

SaiyanMed selects independent testing labs by enforcing a strict, non-negotiable protocol: every single production batch must be sent to a single, vetted third-party laboratory—Janoshik Analytical—for comprehensive purity and mass verification, and the resulting Certificates of Analysis (CoAs) are published openly on the product pages for every researcher to inspect. This isn't a random choice or a marketing gimmick. The selection process is driven by three hard metrics: lab accreditation, methodological transparency, and community trust. Janoshik holds ISO/IEC 17025 accreditation, which means their testing methods (HPLC-MS for purity, LC-MS for identity, and residual solvent analysis) are audited by an external body against international standards. We don't rotate labs or cherry-pick cheaper options. Every batch—from raw peptide raw materials to the final lyophilized powder in the vial—goes through the same gate. If Janoshik flags a batch below our internal threshold of 98.5% purity (most of our products hit 99%+), that batch is quarantined, investigated, and never shipped. This is documented in our internal SOPs, and the data is available on request. You can verify this yourself by pulling any CoA from our product pages and cross-referencing the batch number with Janoshik's public database.

Why Janoshik and not a cheaper local lab? The answer is rooted in data integrity. In the research peptide industry, the biggest problem isn't sourcing raw materials—it's trusting the numbers on the paper. Many suppliers use in-house testing or labs with no public track record, which creates a conflict of interest. We eliminated that conflict by choosing a lab that is entirely independent of our manufacturing chain. Janoshik doesn't manufacture, distribute, or sell peptides. They only test them. Their reports include not just purity percentages but also full chromatograms (the raw UV trace data), mass spectrometry confirmation of molecular weight, and a breakdown of any impurities detected. For example, on a recent batch of our BPC-157 (Lot #SMBP-2409-01), the CoA showed a purity of 99.12%, with the main impurity being a trace amount of residual TFA (trifluoroacetic acid) at 0.34%. That level of detail is standard for us, not exceptional. We also track batch-to-batch consistency. Over the last 12 months, the average purity deviation across all our peptide products is less than 0.4%, which indicates our production process (joint manufacturing partnerships with GMP-compliant facilities) is tightly controlled.

Here is the raw data on our testing frequency and coverage for Q1 2024:

This isn't just about checking a box. The two rejected batches in Q1 were flagged for a slight deviation in residual solvent levels (DCM at 0.12% vs. our internal limit of 0.10%). The raw material supplier was notified, the batch was destroyed, and the production line was re-validated before the next run. That kind of granularity is only possible because we use a lab that reports every detectable compound, not just the target peptide.

How the selection process actually works operationally: It starts with our raw material procurement. We source peptide raw materials from a shortlist of suppliers who themselves use GMP-grade synthesis and provide their own CoAs. Those raw materials are then lyophilized (freeze-dried) in our controlled facility. After lyophilization, a representative sample from each batch is pulled, coded with a blind lot number, and shipped directly to Janoshik in the Czech Republic. The lab doesn't know the product identity or the expected purity—they receive only the sample and a request for a full panel. This blind testing protocol eliminates any possibility of lab bias. Once Janoshik returns the results, our internal quality team compares the data against the raw material CoA. If there's a discrepancy (e.g., the raw material CoA claimed 99.5% purity but Janoshik found 98.2%), we flag the raw material supplier and may delist them. This has happened three times in the last year. The final CoA is then uploaded to the product page on saiyanmed with a clear batch number and a QR code that links directly to Janoshik's verification portal. Researchers can scan that code and see the exact same document we have.

Beyond purity: what else is tested? Purity is the headline number, but it's not the only metric. Every batch is also tested for:

• Identity confirmation: LC-MS to confirm the molecular weight matches the expected peptide sequence within 0.01 Da tolerance.
• Residual solvents: GC-MS to detect any leftover synthesis solvents (acetonitrile, methanol, DCM, etc.). Our limit is 0.1% per solvent, which is stricter than the general pharmacopoeia limit of 0.5%.
• Water content: Karl Fischer titration. Lyophilized peptides are hygroscopic. We require water content below 3% to ensure long-term stability. Most of our batches come in at 1.5-2.5%.
• Endotoxin levels: LAL assay. For research-grade products, we target <1.0 EU/mg. Some products like our Thymosin Alpha-1 are tested to <0.5 EU/mg.
• Mass balance: The sum of all detected components (peptide, water, residual solvents, counterions) should equal 100% ± 2%. This catches any hidden impurities that don't show up on a simple purity scan.

All of these data points are included in the full CoA. We don't publish a summary—we publish the raw report. This is a direct result of how we selected our testing partner. Janoshik's reporting format includes all these parameters by default. If we had chosen a lab that only provided a single purity number, we would have less actionable data. The decision to use a full-panel lab was deliberate and based on the needs of serious researchers who need to know exactly what's in their vial.

Cost vs. value of independent testing: Running a full Janoshik panel on every batch costs us roughly $350-$500 per test, depending on the peptide complexity. For a small supplier, that's a significant expense. For us, it's a fixed cost of doing business. We budget for it as a line item in our production overhead. To put it in perspective, our Q1 2024 testing expenditure was approximately $21,000. That money buys us—and our customers—verifiable data. It also buys us accountability. If a batch fails, we lose the entire production run (raw materials + labor + lyophilization costs), which can be $5,000-$15,000 per batch. The financial incentive to cut corners is real, but we've structured our operations so that the only way to ship a product is to have a passing Janoshik CoA. There is no bypass. Our logistics team cannot generate a shipping label for a batch that hasn't been cleared in our internal database. That's a hard-coded rule in our order management system.

How researchers can verify this themselves: Go to any product page on our site. Look for the "Certificate of Analysis" section. Click the download link. You'll see a PDF that includes the batch number, the test date, the method used (e.g., HPLC-MS), the purity percentage, the full chromatogram, and the lab's stamp. Then go to Janoshik's public verification portal (janoshik.com/verify). Enter the batch number from the CoA. The portal will return the same report. If the report on our site doesn't match the report on Janoshik's site, that's a red flag. In our case, they will match 100% because we don't alter or redact any data. This is the same verification process used by many serious research groups and biohacking communities. We didn't invent it—we adopted it because it's the gold standard for transparency.

What about other labs? We've evaluated other independent labs—including MZ Biolabs, Eurofins, and a few smaller specialized labs. Each has strengths. MZ Biolabs, for example, offers very high-resolution mass spec for complex peptides. But Janoshik was selected for three specific reasons: (1) they specialize exclusively in peptide analysis, meaning their methods are optimized for this class of molecules; (2) they have a public-facing verification system that allows anyone to cross-check results; and (3) their turnaround time is consistently 3-5 business days, which keeps our supply chain moving. We don't use multiple labs for the same product because that introduces variability in testing methodology. A peptide that reads 99% on one HPLC column might read 98.5% on another due to column chemistry differences. By using a single lab with standardized methods, we ensure batch-to-batch comparability. This is a deliberate choice to prioritize consistency over the illusion of "multiple validations."

Real-world example of how this plays out: In October 2023, we received a raw material shipment of Semax from a new supplier. The supplier's CoA showed 99.8% purity. We ran our own in-process test (a quick HPLC scan) and it looked clean. But we still sent a sample to Janoshik as part of our standard protocol. Janoshik's full panel came back with 97.4% purity and a detectable impurity at 1.2% that was identified as a truncated peptide fragment. That fragment wouldn't have shown up on a simple purity scan because it had a similar retention time to Semax. But Janoshik's mass spec identified it by molecular weight. We rejected the entire raw material batch (500 grams), terminated the supplier relationship, and sourced a new supplier. That batch never made it to lyophilization or to any customer. The cost of that rejection was about $8,000 in raw materials and testing. But the cost of shipping a substandard product would have been far higher in terms of research integrity and our reputation. This is why we don't compromise on the lab selection process.

Infrastructure supporting the testing pipeline: Our testing protocol is backed by a physical infrastructure that ensures sample integrity. Samples are shipped in temperature-controlled packaging with gel packs and a data logger. The chain of custody is documented from the moment the sample is pulled to the moment it's received by Janoshik. We use tamper-evident seals and require a signature at delivery. This might seem excessive for a research peptide, but it's standard practice in pharmaceutical quality control. We treat every batch as if it were a clinical trial material because the researchers using it deserve that level of rigor. Our US-based warehouse holds the finished goods, but the testing is done before any product enters that warehouse. So by the time a researcher places an order, the CoA is already published and verified. There is no "testing after shipment" or "CoA pending." Every product listed on our site has a live, verified CoA from Janoshik. If a product page doesn't have a CoA, it means we haven't released that batch for sale yet.

Data transparency beyond the CoA: We also publish aggregate data on our testing results every quarter. This includes the number of batches tested, the average purity, the rejection rate, and the specific reasons for rejection. This is not common in the industry. Most suppliers publish only the good results. We publish everything, including the failures, because we believe that full transparency builds trust. For example, our Q4 2023 report showed a rejection rate of 6.4% (3 out of 47 batches). Two were rejected for residual solvent issues, and one for low purity (97.8%). That data is available on our website under the "Quality" section. We also include a note on what corrective actions were taken—e.g., "Supplier A was delisted due to inconsistent raw material purity." This level of detail is possible because our lab selection process is fixed and our reporting is standardized. If we used multiple labs with different reporting formats, compiling this data would be much harder and less reliable.

How this affects the researcher's experience: When you receive a product from us, you can immediately go to the CoA, scan the QR code, and confirm the batch number matches the vial. You can then check the purity, the impurity profile, and the residual solvents. You can compare that data to your own in-house analysis if you have access to an HPLC. We've had researchers email us asking for the raw UV trace data from the chromatogram, and we provide it. That's not a special request—it's a standard part of our data retention policy. We keep all raw data files (not just the PDF reports) for a minimum of 3 years. This is a direct consequence of selecting a lab that provides raw data, not just summary numbers. Janoshik's reports include the full chromatogram image and the integration table. We store those files in a secure cloud archive. If a researcher needs to audit a batch from 2022, we can pull the data within 24 hours.

The bottom line on lab selection criteria: We chose Janoshik because they meet our non-negotiable requirements: ISO 17025 accreditation, public verification system, full-panel reporting (purity, identity, solvents, water, endotoxins), blind testing capability, and consistent turnaround times. We did not choose them because they are the cheapest or the fastest. We chose them because they are the most transparent and the most trusted by the research community. That trust is earned through years of consistent performance and a willingness to publish data that other labs might hide. We have no plans to change labs unless a better option emerges that meets or exceeds these criteria. And if we do change, we will publish the reason for the change and the data that supports it. That's the standard we hold ourselves to, and it's the standard we expect from our testing partners.